Etrolizumab, a mAb that binds to β7 integrin subunit, can block α4β7-MAdCAM-1 and αEβ7-E-cadherin interactions and is being currently tested for the treatment of IBD and UC in clinical trials [37, 38]. This evidence concerns the gene MADCAM1 and inflammatory bowel disease.